3,256 results match your criteria: "Affiliated Cancer Hospital of Zhengzhou University[Affiliation]"

Article Synopsis
  • Gemcitabine, a common cancer treatment, was analyzed for adverse events (AEs) using the FDA's FAERS database from 2004 to 2023.
  • The study reviewed over 16 million reports, identifying 23,645 cases of gemcitabine-related AEs, with common issues including thrombocytopenia and unexpected problems like abdominal pain.
  • Findings emphasized that gemcitabine can cause various health complications and hospitalizations, which could inform safer clinical practices and improve patient care.
View Article and Find Full Text PDF

Objective: The research focused on a comparative analysis of triage strategies for women with Atypical Squamous Cells of Undetermined Significance (ASC-US) before and after receiving the HPV vaccine, aiming to optimize cervical cancer prevention strategies, especially in resource-limited healthcare settings.

Materials And Methods: Between September 2018 and December 2023, 7,511 women aged 21 years or older who underwent liquid-based cytology for cervical cancer screening were recruited. Women diagnosed with ASC-US were included in the study.

View Article and Find Full Text PDF

Survival comparison between open and thoracoscopic esophagectomy for node-negative esophageal squamous cell cancer: an ambispective cohort study.

Surg Endosc

December 2024

Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Science Avenue, High-tech Development Zone, Zhengzhou, 450001, Henan, China.

Background: It is controversial whether there is a survival difference between open esophagectomy (OE) and thoracoscopic esophagectomy (TE) for esophageal cancer (EC). Therefore, this study aimed to compare the differences in survival and safety between two surgical approaches in patients with node-negative esophageal squamous cell carcinoma (ESCC).

Methods: This ambispective cohort study included 1104 patients with node-negative ESCC who received OE or TE treatment at a Grate-A tertiary hospital in Henan Province between January 2015 and December 2016.

View Article and Find Full Text PDF

Objective: Disulfidptosis was stimulated in high SLC7A11 expression cells starving to glucose. We attempted to identify disulfidptosis-related lncRNAs (DRLs), built a prognostic model to predict survival, and analyzed the tumor microenvironment.

Methods: The TCGA database was utilized to procure the pertinent data.

View Article and Find Full Text PDF

Cell-Based Screen Identifies a Highly Potent and Orally Available ABCB1 Modulator for Treatment of Multidrug Resistance.

J Med Chem

November 2024

Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.

Targeting ABCB1 is a promising strategy in combating multidrug resistance. Our cell-based phenotypic screening led to the discovery of novel triazolo[1,5-]pyrimidone-based ABCB1 modulators. Notably, was identified as a significant contributor to heightened sensitization of human colorectal adenocarcinoma cells (SW620/Ad300) to paclitaxel (IC = 5 nM).

View Article and Find Full Text PDF

The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma.

Nat Commun

October 2024

National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450052, People's Republic of China.

Article Synopsis
  • Esophageal squamous cell carcinoma (ESCC) shows high variability and its complex molecular and immune landscape complicates personalized treatment development.
  • Through genomic and AI-driven analysis of 120 Chinese ESCC cases, researchers identified four subtypes—differentiated, metabolic, immunogenic, and stemness—each with distinct features.
  • The stemness subtype has the worst prognosis and shows immune evasion traits, with high levels of intratumoural diversity, while specific markers like XCL1 influence both immune response and chemotherapy effectiveness.
View Article and Find Full Text PDF

The safety and efficacy of through-and-through wire technique for ureteral Double-J stent placement.

Pak J Med Sci

October 2024

Fang Kun Li, MD Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Objective: To evaluate the efficacy and safety of the through-and-through wire (TTW) technique for antegrade ureteral Double-J stent placement after failure of either antegrade or retrograde ureteral stent placement.

Method: This retrospective study analyzed the medical records of consecutive patients who underwent Double-J stent placement with the TTW technique at Asan Medical Center and Gil Medical Center between January 2016 and February 2023. Patient histories, reasons for employing the TTW technique, TTW pathways, and complications were reviewed.

View Article and Find Full Text PDF

Variant acute promyelocytic leukemia (APL) and APL-like leukemia are rare types of APL, with t (16;17) chromosome abnormality being even rarer. An APL-like patient with t (16;17) chromosome abnormality, which was characterized by bone, lymph node, and central nervous system involvement, was admitted to our hospital. He achieved complete remission after several cycles of chemotherapy and subsequently underwent hematopoietic stem cell transplantation.

View Article and Find Full Text PDF

[The 5-year relative survival rate among cancer patients in Henan province of China, 2015-2019].

Zhonghua Zhong Liu Za Zhi

October 2024

Department of Disease Prevention and Control, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou 450008, China.

To analyze the 5-year relative survival rate of cancer in Henan province based on cancer registration data. Cancer survival data were extracted from the cancer registration database of Henan province with the diagnosis date between January 1, 2010 and December 31, 2019 were included. The closing date of follow-up was set as December 31, 2019.

View Article and Find Full Text PDF

Our goal was to assess the impact of prior cancer history on the prognosis of extranodal NK/T-cell lymphoma (ENKTCL). We searched the SEER database to retrospectively enroll patients with ENKTCL. The effects of cancer history on overall survival (OS) and disease-specific survival (DSS) were analyzed using the Cox model.

View Article and Find Full Text PDF

The Potential and Challenges of Proton FLASH in Head and Neck Cancer Reirradiation.

Cancers (Basel)

September 2024

Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.

Ultrahigh-dose-rate therapy, also known as FLASH radiotherapy (RT), is an emerging technique that is garnering significant interest in cancer treatment due to its potential to revolutionize therapy. This method can achieve comparable tumor control to conventional-dose-rate RT while offering the enhanced protection of normal tissue through the FLASH-sparing effect. This innovative technique has demonstrated promising results in preclinical studies involving animals and cell lines.

View Article and Find Full Text PDF

Hexavalent chromium [Cr(VI)] exposure increases the risk of cancer occurrence. This study found that the levels of an atypical methyltransferase, METTL16 were greatly upregulated in the cells, and mouse tissues with Cr(VI) exposure, and played a critical role in cell proliferation and tumor growth induced by Cr(VI). Similarly, we found METTL16 was upregulated in various human cancer tissues.

View Article and Find Full Text PDF
Article Synopsis
  • * The patient, a 55-year-old female, exhibited elevated serum levels of Pro-Gastrin-Releasing Peptide (pro-GRP), and endoscopic evaluations revealed a mass diagnosed as NETs in the duodenum, along with multiple tumors on the stomach and liver.
  • * After surgery and histopathological analysis confirmed the diagnoses, the patient responded well to targeted therapy and recovered without complications,
View Article and Find Full Text PDF
Article Synopsis
  • CAR-T therapy has improved treatment options for relapsed/refractory B-cell lymphoblastic leukemia, but it can cause serious side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
  • A study involving 93 patients showed that while most (81.7%) experienced CRS and a few (5.3%) experienced ICANS, these conditions did not significantly impact treatment effectiveness or patient survival rates.
  • Ultimately, the findings suggest that experiencing CRS or ICANS does not lead to worse outcomes for patients receiving anti-CD19 CAR-T therapy.
View Article and Find Full Text PDF

RNA methyltransferase NSUN2-mediated m5C methylation promotes Cr(VI)-induced malignant transformation and lung cancer by accelerating metabolism reprogramming.

Environ Int

October 2024

Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou 450000, China. Electronic address:

Article Synopsis
  • - The study investigates how hexavalent chromium [Cr(VI)], a known carcinogen, causes epigenetic changes that contribute to cancer development, specifically focusing on the role of the RNA methyltransferase NSUN2 and its effects on cell behavior.
  • - Researchers found that higher levels of NSUN2 in Cr(VI)-transformed cells and lung tissues positively affect cell proliferation, migration, and tumor growth by modifying RNA stability of certain genes related to metabolism and the cell cycle.
  • - The findings suggest that NSUN2 and its interaction with the m5C reader ALYREF play a critical role in Cr(VI)-induced carcinogenesis, highlighting potential new biomarkers or therapeutic targets for cancer associated with chromium exposure
View Article and Find Full Text PDF

Inflammation plays a crucial role in cancer development. The neutrophil-to-lymphocyte ratio (NLR), a measure of inflammation, is obtained from a complete blood count. However, little is known about the association between NLR and cancer in the general adult population in the United States.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to predict the muscular invasion status of bladder urothelial carcinoma using advanced diffusion-weighted imaging techniques and compare the effectiveness of these techniques with the established VI-RADS system.
  • Patients with confirmed UCB underwent preoperative MRI, and several quantitative imaging parameters were analyzed to distinguish between non-muscle invasive and muscle-invasive cases.
  • The results showed that specific diffusion metrics (Axial diffusivity and Mean diffusivity) were strong predictors for muscle invasion, leading to a new MRI model that outperformed the VI-RADS system in diagnostic accuracy.
View Article and Find Full Text PDF

First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.

Med

January 2025

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China. Electronic address:

Article Synopsis
  • Zorifertinib is an experimental cancer drug that targets mutations in the EGFR gene and has shown effectiveness in patients with lung cancer that has spread to the brain.
  • A phase 3 trial compared zorifertinib to standard treatments and found that it significantly extended the time patients lived without the disease worsening (progression-free survival).
  • Results indicate that zorifertinib may be a better first-line treatment option for non-small cell lung cancer due to its ability to improve survival and manage side effects effectively.
View Article and Find Full Text PDF
Article Synopsis
  • - The MONARCH plus study found that adding abemaciclib to endocrine therapy significantly improved progression-free survival (PFS) and objective response rate (ORR) in postmenopausal women with HR+/HER2- advanced breast cancer.
  • - In the study, cohort A (no prior systemic therapy) showed a median PFS of 28.27 months for abemaciclib users compared to 14.73 months for those on placebo, while cohort B (progression on prior therapy) showed 11.41 months vs. 5.59 months, respectively.
  • - Although abemaciclib was associated with some adverse events, they were manageable, and it demonstrated a trend toward overall survival (OS
View Article and Find Full Text PDF
Article Synopsis
  • - The study explores the interaction between neural infiltration and non-small cell lung cancer (NSCLC), highlighting how infiltrating nerves and tumor cells influence each other, which can lead to tumor growth and spread.
  • - Researchers used various advanced techniques to uncover that nerve growth factor (NGF) promotes neural infiltration in NSCLC, and that increased levels of 5-hydroxytryptamine (5-HT) in tumors enhance tumor cell metabolism, particularly glycolysis, and contribute to a suppressive tumor environment.
  • - The research suggests that targeting 5-HT-mediated changes can improve the effectiveness of PD-1 monoclonal antibody treatment, indicating a potential new strategy for enhancing immunotherapy in NSCLC patients.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the progression of advanced hepatocellular carcinoma (HCC) in patients receiving a combination of local therapies, targeted drugs, and PD-1/PD-L1 inhibitors.
  • It analyzed data from 86 patients treated between 2018 and 2022, focusing on disease progression through imaging and immune cell analysis.
  • Results show that intrahepatic and extrahepatic progression occurred at specific median times, with lymph nodes and lungs being the most affected areas, and notable changes in PD-1+ immune cell percentages were observed post-treatment.
View Article and Find Full Text PDF

Background: The phase 2 PERMEATE study has shown the antitumor activity and safety of pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases. In this report, survival results were updated with extended follow-up.

Methods: Between January 29, 2019 and July 10, 2020, adult patients with HER2-positive metastatic breast cancer who had radiotherapy-naïve brain metastases (cohort A, n = 59) or progressive disease after radiotherapy (cohort B, n = 19) were enrolled and received pyrotinib (400 mg once daily) and capecitabine (1000 mg/m twice daily on days 1-14 of each 21-day cycle) until disease progression or unacceptable toxicity.

View Article and Find Full Text PDF

Background: The effectiveness of sentinel lymph node biopsy (SLNB) versus axillary lymph node dissection (ALND) in managing early-stage male breast cancer (MBC) patients with T1-2 tumors and limited lymph node metastasis, all receiving radiotherapy, remains uncertain. This study examines trends and survival outcomes for SLNB and ALND in the United States.

Methods: We conducted a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data from 2010 to 2020 for MBC patients with T1-2 tumors and 1-2 positive lymph nodes undergoing radiotherapy.

View Article and Find Full Text PDF

Purpose: This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor () mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors (TKIs), compared with TKIs alone, could achieve better survival.

Materials And Methods: The patients in the TKI plus TRT group received 60 Gy to primary lung tumor and positive regional lymph nodes.

View Article and Find Full Text PDF